Roles of Vif Variants and APOBEC3s in HIV-1/AIDS
Roles of Vif Variants and APOBEC3s in HIV-1/AIDS
批准号:
7414558
负责人:
David Kabat
金额:
$33.01万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-07-01 至 2010-04-30
关键词:
AddressAffinity ChromatographyAnti-Retroviral AgentsAntiviral AgentsBindingBinding SitesBiological AssayCell LineCell physiologyCellsCultured CellsCytidine DeaminaseHIV-1HumanImmunofluorescence MicroscopyInflammationInvestigationLymphocyteMass Spectrum AnalysisModelingMutationPathogenesisPatientsPichiaPolyubiquitinationProductionProteinsRNA-Binding ProteinsRecombinantsResourcesRoleSignal TransductionSiteSite-Directed MutagenesisSpecificityStandards of Weights and MeasuresSubgroupSystemT-LymphocyteTissuesTranscriptVariantViralVirusYeastsacrosome stabilizing factorbaseextracellularin vivoinsightmacrophageparalogous geneprograms
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Recent studies have begun to elucidate the role of the HIV-1 encoded viral infectivity factor (Vif)in
neutralizing a potent antiretroviral system that occurs in lymphocytes and macrophages. This system
principally involves the cytidine deaminases APOBEC3G (A3G) and/or ASF, which are incorporated intoHIV-
1 cores where they lethally hypermutate newly synthesized viral reverse transcripts. Vif binds to A3G and
A3F and induces their polyubiquitination and degradation, thereby eliminating them from infected cells and
precluding their incorporation into HIV-1 progeny. The additional APOBEC3 paralogs ASA, A3B, and A3C
have weaker anti-HIV-1 activities in standard assays, and it is believed that their concentrations might also
be relatively low in T cells and macrophages. However, new evidence suggests that APOBEC3 expression
levels and activities can be altered dramatically by extracellular signals and by cell-specific factors.
Therefore, these other APOBEC3 paralogs might potentially influence HIV-1 replication in specific cells or
compartments or during inflammation in some patient tissues. Recently, we found that HIV-1 Vifs use
nonidentical sites to promiscuously bind to all APOBEC3 paralogs and that natural Vif variants degrade
diverse APOBECSs with highly distinctive specificities in a standard assay system. Several mutations in Vif
that eliminate its binding to A3G do not eliminate its binding to ASF, suggesting that these key cytidine
deaminases associate differently with Vif.These and additional recent insights raise important questions
concerning the mechanisms for Vif binding to ASF and A3G, the roles of Vif diversity in patients, and the
identities and functions of cellular factors that associate with A3G and ASF to control their anti-HIV-1
activities. In addition, we have recently succeeded in producing large amounts of Vif and A3G in Pichia
pastoris yeast, which enables structural investigations. Based on these considerations, we propose three
substantive and synergistic aims: (1) Optimize large-scale production and purification of soluble Vif, A3G,
and ASF. Analyze Vif homooligomerization, determine whether Vif associates directly with A3G and/or ASF,
and use these purified proteins in collaborative physical and structural investigations. Employ site-directed
mutagenesis to further analyze these protein interactions. (2) Analyze the role of adaptive Vif variance in
HIV-1 replication in patients and in cell cultures. (3) Use tandem affinity purification and electrospray mass
spectrometry to identify cellular proteins and RNAs that associate with A3G, and analyze the effects of these
proteins and RNAs on anti-HIV-1 activities of A3G and ASF. This program substantively addresses important
issues concerning Vif and APOBEC3 diversities and provides unique approaches and resources for
analyzing their roles in HIV-1 replication and pathogenesis.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.molmed.2004.04.008
发表时间:
2004-06
期刊:
Trends in molecular medicine
影响因子:
13.6
作者:
[K. Rose;M. Marin;S. Kozak;D. Kabat]
通讯作者:
K. Rose;M. Marin;S. Kozak;D. Kabat
Drug development for Vif-APOBEC3G in HIV-1/AIDS
-
批准号:7061978
-
项目类别:
-
资助金额:$36.91万
-
财政年份:2005
-
负责人:David Kabat
-
依托单位:
Drug development for Vif-APOBEC3G in HIV-1/AIDS
-
批准号:7152570
-
项目类别:
-
资助金额:$36.01万
-
财政年份:2005
-
负责人:David Kabat
-
依托单位:
Drug development for Vif-APOBEC3G in HIV-1/AIDS
-
批准号:7321662
-
项目类别:
-
资助金额:$36.33万
-
财政年份:2005
-
负责人:David Kabat
-
依托单位:
Role of Vif in HIV-1 Replication/AIDS
-
批准号:6511565
-
项目类别:
-
资助金额:$26.32万
-
财政年份:2001
-
负责人:David Kabat
-
依托单位:
Role of Vif in HIV-1 Replication/AIDS
-
批准号:6742442
-
项目类别:
-
资助金额:$26.37万
-
财政年份:2001
-
负责人:David Kabat
-
依托单位:
Role of Vif in HIV-1 Replication/AIDS
-
批准号:6408784
-
项目类别:
-
资助金额:$22.96万
-
财政年份:2001
-
负责人:David Kabat
-
依托单位:
Role of Vif in HIV-1 Replication/AIDS
-
批准号:6891314
-
项目类别:
-
资助金额:$26.43万
-
财政年份:2001
-
负责人:David Kabat
-
依托单位:
Role of Vif in HIV-1 Replication/AIDS
-
批准号:6632461
-
项目类别:
-
资助金额:$26.32万
-
财政年份:2001
-
负责人:David Kabat
-
依托单位:
Role of Vif in HIV-1 Replication/AIDS
-
批准号:6346452
-
项目类别:
-
资助金额:$5.25万
-
财政年份:2001
-
负责人:David Kabat
-
依托单位:
Roles of Vif Variants and APOBEC3s in HIV-1/AIDS
-
批准号:7166732
-
项目类别:
-
资助金额:$33.69万
-
财政年份:2001
-
负责人:David Kabat
-
依托单位:
Roles of Vif Variants and APOBEC3s in HIV-1/AIDS
-
批准号:7232104
-
项目类别:
-
资助金额:$32.45万
-
财政年份:2001
-
负责人:David Kabat
-
依托单位:
NEW RETROVIRAL RECEPTORS/HOST RESISTANCES
-
批准号:6497942
-
项目类别:
-
资助金额:$25.42万
-
财政年份:2000
-
负责人:David Kabat
-
依托单位:
NEW RETROVIRAL RECEPTORS/HOST RESISTANCES
-
批准号:6027873
-
项目类别:
-
资助金额:$26.03万
-
财政年份:2000
-
负责人:David Kabat
-
依托单位:
NEW RETROVIRAL RECEPTORS/HOST RESISTANCES
-
批准号:6350407
-
项目类别:
-
资助金额:$24.68万
-
财政年份:2000
-
负责人:David Kabat
-
依托单位:
NEW RETROVIRAL RECEPTORS/HOST RESISTANCES
-
批准号:6628426
-
项目类别:
-
资助金额:$26.17万
-
财政年份:2000
-
负责人:David Kabat
-
依托单位:
NEW RETROVIRAL RECEPTORS/HOST RESISTANCES
-
批准号:6694062
-
项目类别:
-
资助金额:$26.95万
-
财政年份:2000
-
负责人:David Kabat
-
依托单位:
FUNCTIONS OF RETROVIRAL RECEPTORS TRANSPORTERS
-
批准号:6172425
-
项目类别:
-
资助金额:$20.38万
-
财政年份:1997
-
负责人:David Kabat
-
依托单位:
FUNCTIONS OF RETROVIRAL RECEPTORS TRANSPORTERS
-
批准号:2007269
-
项目类别:
-
资助金额:$18.97万
-
财政年份:1997
-
负责人:David Kabat
-
依托单位:
FUNCTIONS OF RETROVIRAL RECEPTORS TRANSPORTERS
-
批准号:2894508
-
项目类别:
-
资助金额:$19.79万
-
财政年份:1997
-
负责人:David Kabat
-
依托单位:
FUNCTIONS OF RETROVIRAL RECEPTORS TRANSPORTERS
-
批准号:6375616
-
项目类别:
-
资助金额:$20.99万
-
财政年份:1997
-
负责人:David Kabat
-
依托单位:
海外基金